RNAZ – transcode therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors [Yahoo! Finance]
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
TransCode Therapeutics Reports 2023 Results; Provides Business Update [Yahoo! Finance]
Form ARS Transcode Therapeutics, For: Dec 31
Form DEF 14A Transcode Therapeutics, For: Jun 13
Form 8-K Transcode Therapeutics, For: Apr 22
Form 8-K Transcode Therapeutics, For: Apr 03
Form 10-K Transcode Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.